Structure-activity relationships of N2-aryl-3-(isoxazolylsulfamoyl)-2- thiophenecarboxamides as selective endothelin receptor-A antagonists

Journal of Medicinal Chemistry

Volumn 40, Issue 11, 1997, Pages 1682-1689

  Wu, Chengde ^a,b   Chan, Ming F ^a   Stavros, Fiona ^a,b   Raju, B ^a,b   Okun, Ilya ^a   Castillo, Rosario S ^a  

^a ImmunoPharmaceutics Inc   (United States)

^b TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 THENOIC ACID AMIDE DERIVATIVE; 3 (ISOXAZOLYLSULFAMOYL) 2 THIOPHENECARBOXAMIDE DERIVATIVE; AMIDE; ENDOTHELIN A RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING, COMPETITIVE; BLOOD PRESSURE; CELL LINE; COS CELLS; ENDOTHELIN-1; ENDOTHELINS; HALF-LIFE; HUMANS; HYDROLYSIS; ISOXAZOLES; MALE; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 0031006108     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9608366     Document Type: Article

References (41)

1. A Selective Endothelin Antagonists. The 211th ACS National Meeting, New Orleans, LA, March 24-28, 1996, Abstract MEDI 146.
2. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Goto, K.; Masaki, T. A. Novel Potent Vasoconstrictor Peptide Produced by Vascular Endothelin Cells. Nature 1988, 332, 311-415.
3. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. The Human Endothelin Family: Three Structurally and Pharmacologically Distinct Isopeptides Predicted by Three Separate Genes. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 2863-2867.
4. Watanabe, T.; Suzuki, N.; Shimamoto, N.; Fujino, M.; Imada, A. Endothelin in Myocardial Infarction. Nature 1990, 344, 114.
5. Saito, Y.; Nakao, K.; Mukoyama, M.; Imura, H. Increased Plasma Endothelin Level in Patients with Essential Hypertension. N. Engl. J. Med. 1989, 322, 205.
6. Giaid, A.; Yanagisawa, M.; Langleben, D.; Michel, R.; Levy, R.; Shennib, H.; Kimra, S.; Masaki, T.; Duguid, W.; Path; F. R. C.; Stewart, D. J. Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension. N. Engl. J. Med. 1993, 328, 1732-1739.
7. Takahashi, K.; Totsune, K.; Mouri, T. Endothelin in Chronic Renal Failure. Nephron 1994, 66, 373-379.
8. Cosentino, F.; Katusic, Z. S. Does Endothelin-1 Play a Role in the Pathogenesis of Cerebral Vasospasm? Stroke 1994, 25, 904-908.
9. Clozel, M.; Breu, V.; Burri, K.; Cassao, J.-M.; Fischli, W.; Gray, G. A.; Hirth, G.; Loffler, B.-M.; Muller, M.; Neidhart, W.; Ramuz, H. Pathophysiological Role of Endothelin Revealed by the First Orally Active Endothelin Receptor Antagonist. Nature 1993, 365, 759-761.
10. Arai, H.; Hori, S.; Aramori, I.; Ohkubo, H.; Nakanishi, S. Cloning and Expression of a cDNA Encoding an Endothelin Receptor. Nature 1990, 348, 730-732.
11. Sakurai, T.; Yanagisawa, M.; Takuwa, Y.; Miyazaki, H.; Kimura, S.; Goto, K.; Masaki, T. Cloning of a cDNA Encoding a Non-isopeptide-selective Subtype of the Endothelin Receptor. Nature 1990, 348, 732-735.
12. Sakamoto, A.; Yanagisawa, M.; Sakurai, T.; Takuwa, Y.; Yanagisawa, H.; Masaki, T. Cloning and Functional Expression of Human cDNA for the ETB Endothelin Receptor. Biochem. Biophys. Res. Commun. 1991, 178, 656-663.
13. Hosoda, K.; Nakao, K.; Arai, H.; Suga, S.; Ogawa, Y.; Mukoyama, M.; Shirakami, G.; Saito, Y.; Nakanishi, S.; Imura, H. Cloning and Expression of Human Endothelin-1 Receptor cDNA. FEBS Lett. 1991, 187, 23-26.
14. Ogwa, Y.; Nakao, K.; Arai, H.; Nagakawa, O.; Hosoda, K.; Suga, S.; Nakanishi, S.; Imura, H. Molecular Cloning of a Non-isopeptide Selective Human Endothelin Receptor. Biochem. Biophys. Res. Commun. 1992, 178, 248-255.
15. A Selectivity. Potency and Solubility Enhancing Molifications. J. Med. Chem. 1992, 35, 2139-2142.
16. A Receptor. Life Sci. 1991, 50, 247-255.
17. A Receptor Antagonist. J. Pharmacol. Exp. Ther. 1993, 264, 1040-1046.
18. A Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide. J. Med. Chem. 1994, 37, 329-331.
19. A Receptor Antagonist. J. Pharmacol. Exp. Ther. 1995, 272, 1124-1134.
20. Doherty, A. M.; Patt, W. C.; Edmunds, J. J.; Berryman, K. A.; Reisdorph, B. R.; Plummer, M. S.; Shahripour, A.; Lee, C.; Cheng, X. M.; Walker, D. M.; Haleen, S. J.; Keiser, J. A.; Flynn, M. A.; Welch, K. M.; Hallak, H.; Taylor, D. G.; Reynolds, E. E. Discovery of a Novel Series of Orally Active Non-peptide Endothelin-A Receptor Selective Antagonists. J. Med. Chem. 1995, 38, 1259-1263.
21. Winn, M.; von Geldern, T. W.; Opgenorth, T. J.; Jae, H.-S.; Tasker, A. S.; Boyd, S. A.; Kester, J. A.; Mantei, R. A.; Bal, R.; Sorensen, B. K.; Wu-Wong, J. R.; Chiou, W. J.; Dixon, D. B.; Novosad, E. I.; Hernandez, L.; Marsh, K. C. 2,4-Diarylpyrrolidine-3-carboxylic Acids-Potent ETA Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722. J. Med. Chem. 1996, 39, 1039-1048.
22. Elliott, J. D.; Lago, M. A.; Cousins, R. D.; Gao, A.; Leber, J. D.; Erhard, K. F.; Nambi, P.; Elshourbagy, N. A.; Kumar, C.; Lee, J. A.; Bean, J. W.; DeBrosse, C. W.; Eggleston, K. S.; Brooks, D. P.; Feuerstein, G.; Ruffolo, R. R.; Weinstock, J.; Gleason, J. G.; Peishoff, C. E.; Ohlstein, E. H. 1,3-Diarylindan-2-carboxylic acids, Potent and Selective Non-peptide Endothelin Receptor Antagonists. J. Med. Chem. 1994, 37, 1553-1557.
23. Walsh, T. F.; Fitch, K. J.; Chakravarty, K.; Williangs, D. L.; Murphy; K. A.; Nolan, N. A.; O'Brien, J. A.; Lis, E. V.; Pettibone, D. J.; Kivlighn, S. D.; Gabel, R. A.; Zingaro, G. J.; Krause, S. M.; Siegl, P. K. S.; Clineschmidt, B. V.; Greenlee, W. J. Discovery of L-749,329, a Highly Potent, Orally Active Antagonist of Endothelin Receptors. The 208th ACS National Meeting, Washington, DC, August 21-25, 1994, Abstract MEDI 145.
24. Wash, T. F. Progress in the Development of Endothelin Receptor Antagonists. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: New York, 1995; Vol. 30, pp 91-100.
25. Clozel, M.; Breu, V.; Gray, G. A.; Kalina, B.; Loffler, B.; Burri, K.; Cassal, J.; Hirth, G.; Muller, M.; Neidhart, W.; Ramuz, H. Pharmacological Characterization of Bosentan, a New Potent Orally Active Non-peptide Endothelin Receptor Antagonist. J. Pharmacol. Exp. Ther. 1994, 270, 228-235.
26. Ishikawa, K.; Ihara, M.; Noguchi, K.; Mase, T.; Mino, N.; Saeki, T.; Fukuroda, T.; Fukami, T.; Ozaki, S.; Nagase, T.; Nishikibe, J.; Yano, M. Biochemical and Pharmacological Profile of a Potent and Selective Endothelin B-Receptor Antanonist BQ-788. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4892-4896.
27. Urade, Y.; Fujitani, Y.; Watakabe, T.; Umemura, I.; Takai, M.; Okada, T.; Sakata, K.; Karaki, H. An Endothelin B Receptor Selective Antagonist: IRL 1038, (Cys11-Cys15)-endothelin-1 (11-21). FEBS Lett. 1992, 311, 12-16.
28. Clozel, M.; Breu, V. The Role of ET-B Receptors in Normotensive and Hypertensive Rats as Revealed by the Non-peptide Selective ET-B Receptor Antagonist Ro 46-8443. FEBS Lett. 1996, 383 (1-2), 42-45.
29. Breu, V.; Clozel, M.; Burri, K.; Hirth, G.; Neidhart, W.; Ramuz, H. In Vitro Characterisation of Ro 46-8443, the First Non-peptide Antagonist Selective for the Endothelin ET-B Receptor. FEBS Lett. 1996, 383 (1-2), 37-41.
30. B Selective Endothelin Antagonists. The 209th ACS National Meeting, Anaheim, California, April 1995, Abstract MEDI 168.
31. Chan, M. F.; Kois, A.; Raju, B.; Castillo, R. S.; Verner, E. J.; Wu, C.; Venkatachalapathi, Y. V.; Okun, I.; Stavros, F. D.; Balaji, V. N. N-(5-Isoxazolyl)biphenylsulfonamides, N-(3-Isoxazolyl)-biphenylsulfonamides and Derivatives thereof that Modulate the Activity of Endothelin. US Patent 5,464,853, Nov 7, 1995.
32. Chan, M. F.; Raju, B.; Kois, A.; Verner, E. J.; Wu, C.; Castillo, R.; Balaji, V. N. N-(4-Halo-Isoxazolyl)sulfonamides and Derivatives thereof that Modulate the Activity of Endothelin. US Patent 5514691, May 7, 1996.
33. Chan, M. F.; Raju, B.; Kois, A.; Castillo, R. S.; Verner, E. J.; Wu, C.; Hwang, E.; Okun, I.; Stavros, F.; Balaji, V. N. Halogen Substitution at the Isoxazole Ring Enhances the Activity of N-(Isoxazolyl)sulfonamide Endothelin Antagonists. Bioorg. Med. Chem. Lett. 1996, 6 (20), 2393-2398.
34. Verner, E. J.; Kois, A.; Raju, B.; Wu, C.; Yalamori, V.; Castillo, R.; Hwang, E.; Okun, I.; Stavros, F. D.; Balaji, V. N.; Wolff, M. F.; Chan, M. F. Design and Synthesis of Benzenesulfonamides as Endothelin Antagonists. The 208th ACS National Meeting, Washington, D.C., August 21-25, 1994, Abstract MEDI 215.
35. Raju, B.; Wu, C.; Kois, A.; Verner, E.; Okun, I.; Stavros, F.; Chan, M. F. Thiophenesulfonamides as Endothelin Receptor Antagonists. Bioorg. Med. Chem. Lett. 1996, 6 (22), 2651-2656.
36. A Selective Endothelin Antagonists. The 211th ACS National Meeting, New Orleans, LA, March 24-28, 1996, Abstract MEDI 145.
37. Brown, H. C.; Heim, P. J. Am. Chem. Soc. 1964, 86, 3566-3567.
38. DiCarlo, V. S.; Chen, S. J.; Meng, Q. C.; Durand, J.; Yano, M.; Chen, Y. F.; Oparil, S. ETA-receptor Antagonist Prevents and Reverses Chronic Hypoxia-induced Pulmonary Hypertension in Rat. Am. J. Physiol. 1995, 269 (5 Pt 1), L690-697.
39. Oparil, S.; Chen, S. J.; Meng, Q. C.; Elton, T. S.; Yano, M.; Chen, Y. F. Endothelin-A Receptor Antagonist Prevents Acute Hypoxia-induced Pulmonary Hypertension in the Rat. Am. J. Physiol. 1995, 268 (1 Pt 1), L95-100.
40. Stavros, F. D.; Hasel, C. W. O.; Okun, I.; Baldwin, J.; Freriks, K. COS-7 Cells Stable Transfected to Express the Human ET-B Receptor Provide a Useful Screen for Endothelin Receptor Antagonists. J. Cardiovasc. Pharmacol. 1993, 22 (suppl. 8).
41. Berridge, J. M.; Downes, C. P.; Hanley, M. R. Biochem. J. 1982, 206, 587-595.